The company has created a proprietary oral vaccine technology using adenovirus, eliminating the need for cold storage, needles, and medical personnel for administration. Founded in 2007 and headquartered in Gaithersburg, Maryland, PaxVax aims to protect and enhance life by providing specialized oral vaccines that target various viral or bacterial protein antigens. Recently, PaxVax was acquired by Emergent BioSolutions, a global specialty biopharmaceutical company with a mission to address medical needs and emerging health threats, offering specialized products to healthcare providers and governments.